Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GlucoTrack, Inc. - Common Stock
(NQ:
GCTK
)
0.4149
-0.0621 (-13.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GlucoTrack, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
Today 8:49 EDT
From
Lōkahi Therapeutics Inc.
Via
Business Wire
The trading volume of these stocks is deviating from the norm in today's session.
↗
July 31, 2026
Via
Chartmill
Top stock movements in today's session.
↗
July 31, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 30, 2026
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 30, 2026
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap...
Via
Benzinga
Here are the top movers in Thursday's session.
↗
July 30, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
July 30, 2026
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
July 30, 2026
Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares...
Via
Benzinga
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
July 29, 2026
From
Lōkahi Therapeutics Inc.
Via
Business Wire
What's going on in today's pre-market session
↗
July 20, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
July 17, 2026
Via
Chartmill
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
July 17, 2026
From
Glucotrack, Inc.; Lōkahi Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 16, 2026
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased...
Via
Benzinga
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
July 16, 2026
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and...
From
Glucotrack, Inc.; Lōkahi Therapeutics
Via
GlobeNewswire
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
July 14, 2026
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and...
From
Glucotrack, Inc.; Lōkahi Therapeutics
Via
GlobeNewswire
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
July 08, 2026
From
Glucotrack, Inc.
Via
GlobeNewswire
Top movers in Thursday's after hours session
↗
June 11, 2026
Via
Chartmill
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
May 26, 2026
From
Glucotrack, Inc.
Via
GlobeNewswire
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
May 07, 2026
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform
From
Glucotrack, Inc.
Via
GlobeNewswire
Wednesday's session: most active stocks
↗
May 06, 2026
Via
Chartmill
Unusual volume stocks in Wednesday's session
↗
May 06, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Wednesday's session.
↗
May 06, 2026
Via
Chartmill
Wednesday's session: gap up and gap down stocks
↗
May 06, 2026
Via
Chartmill
These stocks are moving in today's pre-market session
↗
May 06, 2026
Via
Chartmill
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
April 30, 2026
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission
From
Glucotrack, Inc.
Via
GlobeNewswire
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
April 30, 2026
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
April 29, 2026
Via
Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session.
↗
April 29, 2026
Via
Chartmill
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
April 21, 2026
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and...
From
Glucotrack, Inc.
Via
GlobeNewswire
Tuesday's session: gap up and gap down stocks
↗
April 14, 2026
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.